Dr. Pegram on the Development of Trastuzumab Biosimilars
April 29th 2019Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford's Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women's Cancer Center, discusses the development of trastuzumab biosimilars.
Read More
Dr. Pegram on Promising Novel Agents in HER2+ Metastatic Breast Cancer
March 22nd 2019Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.
Read More
Dr. Pegram Discusses Challenges Once Biosimilars Hit US Market
January 19th 2019Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses challenges biosimilars will face once they hit the United States market.
Read More
Dr. Pegram on the Manufacturing Process of Biosimilars
December 6th 2018Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the manufacturing process of biosimilars.
Read More
Dr. Pegram on Projections of Cost Reductions With Biosimilars
December 4th 2018Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses projections of cost reductions with biosimilars.
Read More
Dr. Pegram on Future Impact of Biosimilars in Oncology
November 13th 2018Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the future impact of biosimilars in oncology.
Read More
Dr. Pegram Discusses the Use of Neratinib in HER2+ Breast Cancer
May 23rd 2018Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.
Read More
Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast Cancer
May 11th 2018Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.
Read More
Dr. Pegram on Developing Agents for Patients With HER2+ Breast Cancer and Brain Metastases
April 2nd 2018Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.
Read More
Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer
August 11th 2017Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.
Read More
Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer
July 15th 2017Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.
Read More